GLYPHCBD
Live / Allowed — Notice of allowance issued (as of 24 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 26 Nov 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99518265
- Mark type
- Stylized text
- Filed
- 26 Nov 2025
- Published for opposition
- 27 Jan 2026
- Attorney of record
- Nicholas B. Hawkins
Goods and services
- Class 005 — Pharmaceuticals: Technologies in the nature of pharmaceutical preparations of drugs that facilitate the delivery of pharmaceutical compounds for oral administration of therapeutics utilizing the lymphatic system to treat human and animal disease and illness, namely infectious diseases, inflammatory disorders, respiratory diseases, cardiovascular diseases, autoimmune disorders, gastrointestinal disorders, cancer, hematological diseases, neurological diseases, neuropsychiatric disorders, hepatic diseases, renal diseases, lymphatic disorders, metabolic disorders, genetic disorders, dermatological disorders, ocular diseases, and orphan diseases
- Class 042 — Scientific and technological services: Research and development in the pharmaceutical and biotechnology fields; medical and scientific research in the field of clinical trials
Owner
- Seaport Therapeutics, Inc., Boston, MA, US
- Seaport Therapeutics, Inc., Boston, MA, US
Prosecution history
- 24 Mar 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 27 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 27 Jan 2026 — PUBLISHED FOR OPPOSITION
- 21 Jan 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 02 Jan 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 30 Dec 2025 — ASSIGNED TO EXAMINER
- 26 Nov 2025 — APPLICATION FILING RECEIPT MAILED
- 26 Nov 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 26 Nov 2025 — NEW APPLICATION ENTERED